Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
1 hedge funds and large institutions have $0 invested in Novelion Therapeutics Inc. Common Shares in 2020 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 6 closing their positions.
86% less funds holding
Funds holding: 7 → 1 (-6)
100% less capital invested
Capital invested by funds: $5.45M → $0 (-$5.45M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.76M |
| 2 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
-$2.57M |
| 3 |
DMK
David M. Knott
|
-$77K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$28K |
| 5 |
FSA
Franklin Street Advisors
Chapel Hill,
North Carolina
|
-$18K |
NVLN Hedge Fund Activity: Q1 2020 in Review
1 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q1 2020, worth a combined $0 — down 100% from $5.45M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NVLN and 0 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.76M sold.
- 1 institutional investor held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q1 2020, down from 7 in Q4 2019.
- Funds reported $0 of Novelion Therapeutics Inc. Common Shares stock for Q1 2020, down 100% quarter-over-quarter.
- 0 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q1 2020 and 6 closed out, a net change of -6 holders.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q1 2020 was Stonepine Capital Management, an estimated $2.76M sold.
Based on aggregated 13F filings for Q1 2020.